MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

9.79 0.1

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.69

Максимум

10.08

Ключови измерители

By Trading Economics

Приходи

-2M

-13M

Служители

42

EBITDA

-2.1M

-13M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+329.45% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-129M

840M

Предишно отваряне

9.69

Предишно затваряне

9.79

Настроения в новините

By Acuity

25%

75%

73 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.10.2025 г., 20:45 ч. UTC

Печалби

Costco Wholesale Sales Climb in September, Early October

8.10.2025 г., 20:12 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

TaskUs Shares Fall After Holders Reject Take-Private Deal

8.10.2025 г., 16:39 ч. UTC

Значими двигатели на пазара

Mining Shares Rise as Gold Prices Soar

8.10.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen -- Market Talk

8.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Falls on Possible Profit-Taking -- Market Talk

8.10.2025 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Finance Acquisition Using Internal Funds

8.10.2025 г., 23:17 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8.10.2025 г., 23:16 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8.10.2025 г., 21:54 ч. UTC

Пазарно говорене
Печалби

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8.10.2025 г., 21:30 ч. UTC

Пазарно говорене

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8.10.2025 г., 21:26 ч. UTC

Пазарно говорене
Печалби

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.10.2025 г., 19:15 ч. UTC

Пазарно говорене

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8.10.2025 г., 19:01 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8.10.2025 г., 18:47 ч. UTC

Пазарно говорене

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Will Remain a Publicly Traded Co >TASK

8.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8.10.2025 г., 18:07 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Edging Up in September -- Market Talk

8.10.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

8.10.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.10.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.10.2025 г., 15:57 ч. UTC

Пазарно говорене

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8.10.2025 г., 15:56 ч. UTC

Пазарно говорене

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8.10.2025 г., 15:53 ч. UTC

Пазарно говорене

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8.10.2025 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8.10.2025 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8.10.2025 г., 15:43 ч. UTC

Придобивния, сливания и поглъщания

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8.10.2025 г., 15:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

329.45% нагоре

12-месечна прогноза

Среден 42 USD  329.45%

Висок 42 USD

Нисък 42 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

1

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

73 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat